IL17A and psoriasis: Furthermore, cytokines like IL-17A and IL-23 are also key players in psoriasis, and therapeutic interventions targeting these cytokines and their receptors such as ustekinumab, guselkumab, tildrakizumab, and risankizumab presently provide relief to patients [28].